Medigene AG presents final Phase I data of TCR-T cell
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levels
No neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early response on treatment at week 4, of…